To start, we introduce you to GEAR online resource’s several features:
Do you want to understand a little more on what GEAR can offer to you? Watch this animation that explains in the simplest way possible the features of GEAR.
The definitive guide to equity methods in health economic evaluation - a landmark in the field. Michael Drummond, Professor of Health Economics, University of York, UK
A thorough and accessible overview; the introductory chapters should be part of any graduate-level course on health economic evaluation. Milton Weinstein, Research Professor of Health Policy and Management, Harvard University, USA
How do we conceptualize ideas and find solutions? We map them out!
The mind map feature of the GEAR online resource provides users with a way to address their challenges through short-term and long-term solutions visually represented through the mind map. The right-side provides researchers with immediate solutions for their current challenges based on available information. The left-side shows researchers which questions arise from the methodological challenges presented and the hypotheses they are based on.
Want to learn more? Click here!
The Central Social Insurance Medical Council (Chuikyo) under the Japanese Ministry of Health and Labour Welfare determines the official price and pricing system (for any changes) of drugs and medical devices. Effective ways for them to keep healthcare expenditure low in the face of Japan's aging society and the development of new, high-priced technologies are of increasing interest and importance. Since 2016, the Council has implemented economic evaluations on a trial basis to address this concern (Shiroiwa et al).
The Special Committee on Cost-Effectiveness Evaluation, a subcommittee within the Chuikyo comprised of representatives from "healthcare payers [...], health care professionals [...], and public interest groups (e.g. academics)" as well as non-voting industry representatives and health economists, have discussed and built consensus on the use of economic evaluations for future re-pricing of drugs, medical devices, as well as interventions using expensive medical devices (by 2018). This Chuikyo-approved guideline is required when manufacturers and other groups submit cost-effectiveness analyses to the council (Shiroiwa et al).
Source: Shiroiwa, Takeru, et al. "Development of an official guideline for the economic evaluation of drugs/medical devices in Japan." Value in Health 20.3 (2017): 372-378.
In most low- and middle-income countries, challenges exist in provision of healthcare, which exacerbate difficulties in coordinating data collection and management in the public and private sectors. D...
Recently, results of economic studies addressing questions such as “what interventions or care should be reimbursed by the health insurance packages?” are being validated by policy-makers. Commonl...
This may primarily be due to a lack of coordination as well as lack of process and guidelines on a national level for the studies being conducted. Developing process and guidelines are also resource a...